| Autor: |
FOSSÅ, SOPHIE D., KULLMANN, G., LIEN, H. H., STENWIG, ANNA E., OUS, S. |
| Zdroj: |
British Journal of Urology; 1989, Vol. 64 Issue 5, p530-534, 5p |
| Abstrakt: |
- The predictive significance of the mass detected following chemotherapy was assessed in 46 patients with advanced seminoma. Patients with residual viable seminoma in the post-chemotherapy operation specimen or who developed recurrent disease were regarded as chemotherapy failures. This group included 1 of 20 patients in whom the retroperitoneal masses were ≤ 10 cm2 3 to 4 weeks after chemotherapy and 4 of 15 patients whose residual masses were >10cm2. Four of 11 patients with mediastinal tumours achieved a complete remission (mediastinal masses ≤ 1 cm2). However, 2 of these 4 patients relapsed, as did 2 of the 4 who achieved a partial remission. In no case was the original size of the tumour significantly related to treatment failure. Three patients had residual lung masses; 1 of these contained histological evidence of viable tumour. In one-third of the irradiated relapse-free patients, slightly enlarged masses were visible on follow-up computed tomography scans taken several years after treatment, even in patients without tumour activity. There is a 25% risk of relapse in patients with advanced seminoma who have retroperitoneal masses > 10 cm2 following cisplatin-based chemotherapy. They should be followed up regularly for many years. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text